Details

Autor(en) / Beteiligte

• MEHTA, SANJEEV N.
• KRUGER, DAVIDA F.
• BODE, BRUCE W.
• LAYNE, JENNIFER E.
• DUMAIS, BONNIE
• GALLAGHER, JACK R.
• LY, TRANG T.

Titel

1061-P: Effect of the Omnipod® Insulin Management System on Glycemic Control in Adults with Type 1 Diabetes Previously Treated with MDI or CSII

Ist Teil von

• Diabetes (New York, N.Y.), 2019-06, Vol.68 (Supplement_1)

Ort / Verlag

New York: American Diabetes Association

Erscheinungsjahr

2019

Quelle

EZB*

Beschreibungen/Notizen

• This multi-site, retrospective study evaluated the effect of treatment with a tubeless insulin pump (Omnipod Insulin Management System, Insulet Corp., Acton, MA) on glycemic control in adults with type 1 diabetes (n=166) compared to prior treatment with multiple daily injections (MDI) (63%) or continuous subcutaneous insulin infusion (CSII) (37%). The primary outcome was change in A1C from baseline to 12 months post-Omnipodinitiation. Secondary outcomes included change in A1C at 3- and 6-months, and change in A1C stratified by baseline A1C and prior treatment with MDI or other CSII. Baseline characteristics were mean±SD: age 44±14 y, diabetes duration 24±14 y, 57% female, A1C 8.1±1.5%. The decrease in A1C at 12 months post-Omnipod therapy was -0.2±1.2% (8.1±1.5% vs. 7.9±1.3%; p=0.01) compared to prior treatment. A decrease in A1C was observed at 3- and 6-mo: -0.3±1.2% (n=95; p=0.005) and -0.3±1.1% (n=87; p=0.04), respectively. The within group reduction in A1C at 12 months for prior MDI use was -0.35% (8.1±1.5% vs. 7.8±1.2%; p=0.008) vs. -0.03% (8.0±1.4% vs. 8.0±1.5%; p=0.761) for CSII. The proportion of patients grouped by A1C category is shown in the Figure. In conclusion, long-term use of the Omnipod System was associated with significant improvement in A1C in adults with type 1 diabetes, most notably in those with A1C ≥9.0% and those previously treated with MDI. Disclosure S.N. Mehta: None. D.F. Kruger: Advisory Panel; Self; Abbott, Boehringer Ingelheim Pharmaceuticals, Inc., Insulet Corporation. Consultant; Self; CeQur Corporation, Hygieia. Speaker's Bureau; Self; AstraZeneca, Dexcom, Inc., Eli Lilly and Company. Stock/Shareholder; Self; Dexcom, Inc. Other Relationship; Self; Novo Nordisk Inc. B.W. Bode: Consultant; Self; ADOCIA, Lexicon Pharmaceuticals, Inc., Novo Nordisk Inc. Research Support; Self; Becton, Dickinson and Company, Dexcom, Inc., Diasome Pharmaceuticals, Inc., Eli Lilly and Company, Eyenuk Inc., Insulet Corporation, National Institutes of Health, Novo Nordisk Inc., Sanofi Research & Development, Senseonics, Xeris Pharmaceuticals, Inc. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi US, Senseonics. Stock/Shareholder; Self; AgaMatrix, Glytec, LLC. J.E. Layne: Employee; Self; Insulet Corporation. B. Dumais: None. J.R. Gallagher: None. T.T. Ly: Employee; Self; Insulet Corporation. Funding Insulet Corporation